Advertisement
A or DHR or IQV
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher (DHR) vs. IQVIA (IQV) Stock Comparison
Key Takeaways
- All three stocks provide exposure to life sciences, diagnostics, and healthcare analytics, but DHR leads with the largest market capitalization at approximately $124 billion.
- IQV offers the lowest price-to-earnings (PE) ratio at 20.12 times trailing twelve months (TTM) earnings, indicating potential relative value.
- Recent market activity shows modest declines across the group, with A down about 16% year-to-date (YTD) and flat over the past month.
- DHR reported stronger-than-expected Q1 2026 results, supporting near-term stability amid acquisition pursuits.
- Analyst sentiment remains constructive, with price target upgrades for A and positive outlooks for IQV's AI initiatives.
- Sector headwinds from biopharma spending temper momentum, highlighting valuation sensitivity as a key differentiator.
Introduction
In the competitive landscape of healthcare and life sciences, Agilent Technologies (A), Danaher (DHR), and IQVIA (IQV) stand out as key players offering diagnostics, research tools, and data analytics. This comparison is particularly relevant for investors and traders eyeing sector rotation opportunities amid fluctuating biopharmaceutical demand and technological advancements in drug development. With shared exposure to diagnostics and analytics, these stocks provide insights into relative performance, valuation trade-offs, and growth potential in a market sensitive to R&D spending cycles and macroeconomic pressures.
A Overview and Recent Performance
Agilent Technologies (A) specializes in application-focused solutions for life sciences, diagnostics, and applied chemical markets, operating through segments like Life Sciences and Applied Markets. Its offerings include chromatography systems, mass spectrometry, and lab informatics. In recent market activity, the stock has traded near the lower end of its 52-week range (104-160), reflecting broader sector pressures with a year-to-date decline of around 16% and minimal change over recent weeks. Sentiment has been influenced by Q1 fiscal 2026 results showing 7% reported revenue growth, though core growth was softer at 4.4%, alongside upcoming Q2 earnings on May 27. Analyst upgrades, including targets up to $134, signal optimism around cancer research collaborations and steady demand for consumables.
DHR Overview and Recent Performance
Danaher (DHR) is a diversified conglomerate designing products and services across biotechnology, life sciences, and diagnostics, with brands like Beckman Coulter and Leica Microsystems. Recent weeks have seen the stock pull back about 6% amid euro debt issuance for its potential Masimo acquisition, trading within a 52-week range of 175-243. Q1 2026 earnings beat expectations with EPS of $2.06 versus $1.94 estimated, prompting raised guidance and highlighting bioprocessing recovery. Market sentiment reflects caution over a $908 million charge but supports resilience from diversified segments and strong order trends.
IQV Overview and Recent Performance
IQVIA (IQV) delivers clinical research, analytics, and healthcare intelligence through technology solutions, R&D services, and contract sales. Operating in a 52-week range of 135-247, the stock has experienced volatility in recent market activity, dipping on AI-related concerns despite in-line prior results. Key developments include the launch of IQVIA.ai platform and Q1 2026 earnings due May 5, with expected EPS growth of 4.8%. Sentiment balances growth in real-world data demand against leverage risks and competitive dynamics in healthcare services.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from its library of over 351 bots that trade thousands of tickers across diverse strategies. Only the most suitable for current conditions—such as AI infrastructure, semiconductors, industrials, and volatility plays—earn a spot in this dynamic section, which currently features around 25 high-conviction agents. Stats showcase impressive ranges: annualized returns from 23.53% to 163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70, with timeframes from minutes to weeks and styles including swing trading, multi-ticker agents, and leveraged ETFs. These bots employ risk management like take-profit/stop-loss corridors, offering copy-trading signals for various risk appetites. Traders can explore these tools to align with market trends.
Head-to-Head Comparison
A, DHR, and IQV share life sciences exposure but diverge in models: A emphasizes hardware like spectrometers, DHR leverages M&A-driven scale across instruments and biotech tools (M&A refers to mergers and acquisitions), and IQV focuses on data-driven services. Growth drivers include biopharma R&D, but recent momentum favors none decisively amid sector dips. Risks encompass spending slowdowns, with DHR most diversified, IQV sensitive to tech disruption, and A to consumables cycles. Valuation contrasts show IQV cheapest (PE 20x), DHR priciest (34x), reflecting stability premiums. Sentiment tilts positive on catalysts like DHR deals versus execution hurdles.
Tickeron AI Verdict
Tickeron’s AI currently leans toward DHR based on trend consistency from earnings beats, diversified positioning, and acquisition catalysts, positioning it favorably amid sector volatility. While A shows revenue edge and IQV value appeal, DHR’s scale suggests higher probability of relative outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and IQV’s FA Score reflects 0 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
- IQV’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 6 bullish TA indicator(s), and IQV’s TA Score reflects 6 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- DHR’s TA Score: 6 bullish, 4 bearish.
- IQV’s TA Score: 6 bullish, 2 bearish.
Price Growth
A (@Medical Specialties) experienced а +7.04% price change this week, while DHR (@Medical Specialties) price change was +10.97% , and IQV (@Medical Specialties) price fluctuated +13.93% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +8.88%. For the same industry, the average monthly price growth was +11.83%, and the average quarterly price growth was +6.31%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
DHR is expected to report earnings on Jul 21, 2026.
IQV is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Medical Specialties (+8.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | IQV | |
| Capitalization | 38.4B | 139B | 31.9B |
| EBITDA | 1.96B | 7.08B | 3.52B |
| Gain YTD | 0.363 | -13.937 | -15.203 |
| P/E Ratio | 25.40 | 37.44 | 20.85 |
| Revenue | 7.23B | 24.8B | 16.6B |
| Total Cash | 1.81B | N/A | 2.1B |
| Total Debt | 3.36B | 18.5B | 16.1B |
A | DHR | IQV | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 32 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 10 Undervalued | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 97 | 100 | 100 | |
SMR RATING 1..100 | 44 | 80 | 42 | |
PRICE GROWTH RATING 1..100 | 43 | 51 | 47 | |
P/E GROWTH RATING 1..100 | 62 | 56 | 53 | |
SEASONALITY SCORE 1..100 | 50 | 4 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as DHR (10) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (57) in the Servicestothe Health Industry industry. This means that A's stock grew similarly to DHR’s and somewhat faster than IQV’s over the last 12 months.
A's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry, and is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that A's stock grew similarly to DHR’s and similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as A (44) in the Biotechnology industry, and is somewhat better than the same rating for DHR (80) in the Medical Specialties industry. This means that IQV's stock grew similarly to A’s and somewhat faster than DHR’s over the last 12 months.
A's Price Growth Rating (43) in the Biotechnology industry is in the same range as IQV (47) in the Servicestothe Health Industry industry, and is in the same range as DHR (51) in the Medical Specialties industry. This means that A's stock grew similarly to IQV’s and similarly to DHR’s over the last 12 months.
IQV's P/E Growth Rating (53) in the Servicestothe Health Industry industry is in the same range as DHR (56) in the Medical Specialties industry, and is in the same range as A (62) in the Biotechnology industry. This means that IQV's stock grew similarly to DHR’s and similarly to A’s over the last 12 months.
| A | DHR | IQV | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 58% | N/A |
| Stochastic ODDS (%) | 1 day ago 66% | 1 day ago 65% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 59% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 55% | 1 day ago 59% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 55% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 53% | 1 day ago 63% |
| Advances ODDS (%) | 1 day ago 60% | 1 day ago 54% | 1 day ago 58% |
| Declines ODDS (%) | 11 days ago 62% | 10 days ago 60% | 10 days ago 65% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 64% | 1 day ago 64% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 49% | 1 day ago 43% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +1.75% | ||
| TMO - DHR | 77% Closely correlated | +1.44% | ||
| A - DHR | 73% Closely correlated | +0.37% | ||
| RGEN - DHR | 68% Closely correlated | +1.20% | ||
| RVTY - DHR | 64% Loosely correlated | -0.45% | ||
| BIO - DHR | 64% Loosely correlated | +0.84% | ||
More | ||||
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +2.53% | ||
| CRL - IQV | 75% Closely correlated | +1.43% | ||
| TMO - IQV | 71% Closely correlated | +1.44% | ||
| MEDP - IQV | 65% Loosely correlated | +1.16% | ||
| RVTY - IQV | 65% Loosely correlated | -0.45% | ||
| A - IQV | 63% Loosely correlated | +0.37% | ||
More | ||||